A Case Series of SGLT2i Improving Hemoglobin in Adults with Myelodysplastic Syndrome
Abstract
INTRODUCTION
The objective of our case series was to assess the change in hemoglobin for adults with myelodysplastic syndrome (MDS) started on a sodium glucose cotransporter 2 inhibitor (SGLT2i) for their diabetes, heart failure, or chronic kidney disease.
CASE PRESENTATION
Five consecutive patients with bone marrow biopsy confirmed low or intermediate risk MDS were referred for consideration of SGLT2i between July 2024 and December 2024. The patients were followed prospectively and had a repeat complete blood count at least 3 months after starting empagliflozin at 10 mg daily. Four of the five patients provided written consent for their results to be published. Median age was 78 years (range 76 to 82 years), three of the four patients were men, and the median baseline hemoglobin was 11.6 g/dL (IQR 9.3-12.8). Over a median duration of 4 months of taking empagliflozin, the median repeat hemoglobin was 12.8 g/dL (IQR 10.3-13.7).
CONCLUSIONS
In our case series of four patients with MDS started on empagliflozin, we observed an increase in hemoglobin for all four patients. Larger studies are needed to assess whether the increase in hemoglobin is sufficiently robust and sustained to reduce a person's need for future red blood cell transfusion or other treatments for MDS.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.